Apnimed

Apnimed is a late-stage clinical pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases. Its sole clinical product candidate, AD109, is an investigational first-in-class, fixed-dose oral combination of aroxybutynin (a novel antimuscarinic) and atomoxetine (a selective norepinephrine reuptake inhibitor), designed to target the neuromuscular defect of obstructive sleep apnea (OSA) by improving upper airway muscle activity. The company describes AD109 as a once-at-bedtime oral pill that, if approved, could be the first oral pharmacological treatment to improve oxygenation during sleep without a mask or device. Apnimed has completed the LunAIRo randomized, double-blind, placebo-controlled, 1-year parallel-arm clinical trial evaluating AD109 versus placebo, and reports dual publication of Phase 3 AD109 data as well as additional Phase 3 data presented at the CHEST Annual Meeting 2025. The company also reports strategic debt financing with HealthCare Royalty Partners to support a potential commercial launch of AD109, if approved.

Apnimed is a late-stage clinical pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases. Its sole clinical product candidate, AD109, aims to revolutionize the treatment of obstructive sleep apnea (OSA) as the potentially first oral therapeutic that treats an underlying cause of OSA. AD109 is an investigational first-in-class, fixed-dose oral combination of aroxybutynin, a novel antimuscarinic, and atomoxetine, a selective norepinephrine reuptake inhibitor, designed to target the neuromuscular defect of OSA by improving upper airway muscle activity to help maintain airway patency and prevent airway collapse during sleep. Apnimed has completed LunAIRo, a randomized, double-blind, placebo-controlled, 1-year parallel-arm clinical trial that evaluated AD109 versus placebo. The company reports dual publication of Phase 3 AD109 data in leading journals, additional Phase 3 AD109 data presented at the CHEST Annual Meeting 2025, and strategic debt financing with HealthCare Royalty Partners to support the potential commercial launch of AD109, if approved.

Late-stage clinical pharmaceutical company focused on novel oral therapies for sleep-related breathing diseases; AD109 positioned as a potential first oral pharmacological treatment for OSA.

Product categories. AD109 (investigational oral therapy for OSA)

1. 1Apnimed: Breathing New Life Into OSA & Moreapnimed.com
2. 2Apnimed: Who We Areapnimed.com
3. 3AD109: A Novel Approach To Improve Oxygenation in OSAapnimed.com
4. 4Obstructive Sleep Apnea: Chris's Storyapnimed.com
5. 5Apnimed (United States)wikidata.org